id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-327349-rxb6zfoc	Au, Lewis	Cancer, COVID-19, and antiviral immunity: the CAPTURE study	2020-09-03		.txt	text/plain	4531	183	32	Inherent perturbations on cell subsets (e.g. lymphoid and myeloid malignancies), or therapy-induced impact on immune states (e.g. immune checkpoint blockade) may provide opportunities to understand contributions of distinct immune compartments and key regulators of the anti-SARS-CoV-2 response. Herein, we aim to provide an overview of knowledge to-date of the clinical features of COVID-19 observed in cancer patients, as well as potential impact of cancer and anti-cancer interventions on the immune response to SARS-CoV-2. However, what has been critically missing in cohort and registry reports to date are data on 1) the true prevalence of SARS-CoV-2 infection in the cancer population, given population screening has not been widely implemented; and 2) the experience of those who remain well (uninfected, asymptomatic or subclinically affected), to determine the drivers of mortality and the absolute risks of severe adverse events within the cancer community as a whole. A longitudinal understanding of the degree to which the immunocompromised states of cancer patients impact infection, viral clearance, clinical course of COVID-19, and subsequent generation of long-term immunity is needed.	./cache/cord-327349-rxb6zfoc.txt	./txt/cord-327349-rxb6zfoc.txt